Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Sanitation: Strategies for COVID 2.0 and Beyond

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon. And what…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
The Future of Sanitation: Strategies for COVID 2.0 and Beyond

COVID-19 – remember when that was still a thing? Everyone thought for sure they’d be saying that by now. But, with daily cases in the U.S. reaching all-time highs and a vaccine rollout that will take much longer than desired, getting things back to a semblance of normalcy isn’t happening anytime soon.

And what does normalcy even look like in a COVID 2.0 world, anyway? What are the continuing safety measures businesses, hospitals and schools need to do to keep people safe now and into the future? John Shanahan, President and CEO of Ionogen, and Dr. Jack Lacey, retired CMO of the University of Tennessee’s Medical Center, spoke about the situation and how air sanitation can help keep spaces COVID-free.

New COVID variants are a reminder that the battle against the virus will be a lengthy one, and people need every weapon they can to fight it.

“COVID 1, COVID 2, what makes this virus unique is its ability to hang in the air,” Shanahan said. “We now know we have to take a responsible approach to cleaning the air.”

The bottom line is, even if everything else about an indoor space is clean and sanitized, if the air inside isn’t, COVID can travel and spread.

“COVID-19 most commonly spreads through close human contact and, specifically, through breathing and respiratory droplets,” Dr. Lacey said. “We know that the larger droplets can fall out of the air within the six feet we’re told to distance ourselves, but the much smaller droplets and viral particles can hang in the air for minutes to hours.”

Ionogen’s ionpure line of safe, non-hazardous sanitation products can help fight the coronavirus in the air and on surfaces to make spaces safer for people in facilities of all industries and settings.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Three significant transactions occurred in the pharmaceutical and medtech sectors on August 3, highlighting a split M&A market. While mid-market buyouts such as KKR's acquisition of Integer Holdings and Curium's purchase of Lantheus proceeded, larger megamergers like AstraZeneca's faced obstacles. This suggests a trend towards restructuring within the industry.

  • 01KKR acquired Integer Holdings for $5.7 billion.
  • 02Curium purchased Lantheus in an $8 billion deal.
  • 03AstraZeneca's megamerger attempt was blocked.

Aug 3, 2026

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

CMS centralizes AI and interoperability under a new Office of Health Technology and Products

The Centers for Medicare & Medicaid Services (CMS) has established the Office of Health Technology and Products to integrate AI, interoperability, and digital strategies. This new office aims to enhance efficiency across Medicare, Medicaid, and CHIP programs. By centralizing these efforts, CMS seeks to improve healthcare delivery and outcomes.

  • 01The CMS has launched a new office focusing on AI and interoperability.
  • 02The Office of Health Technology and Products will support Medicare, Medicaid, and CHIP programs.
  • 03Centralizing digital strategies aims to improve healthcare delivery and outcomes.

Aug 1, 2026

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

CMS centralizes health tech authority in new office covering AI, interoperability, and claims modernization

The Centers for Medicare & Medicaid Services (CMS) has established a new Office of Health Technology and Products. This office assumes over 90 responsibilities to lead federal health IT strategy, focusing on areas like AI, interoperability, and claims modernization.

  • 01CMS's new office centralizes health tech authority, focusing on AI and interoperability.
  • 02The office takes on over 90 responsibilities to modernize claims processes.
  • 03CMS aims to lead federal health IT strategy with its new dedicated office.

Aug 1, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512